This editorial describes the science behind a study of the monoclonal antibody nipocalimab to postpone or prevent intrauterine transfusion in pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn.
The New England Journal of Medicine: Search Results in Hematology/Oncology
